My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

22.11 -0.21 (-0.96%)

Streaming Delayed Price Updated: 3:32 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking ↗

July 30, 2022

CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148...

Via Talk Markets

PayPal, Alphabet And Some Other Big Stocks Recording Gains On Wednesday ↗

July 28, 2022

U.S. stocks closed sharply higher on Wednesday, with the Dow Jones jumping more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Short Volatility Alert: Legend Biotech Corporation ↗

June 24, 2022

On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went up +6.97% to $51.10. The...

Via Benzinga

Legend Biotech Shares Move Higher After Bullish BMO Pitch ↗

June 17, 2022

Via Benzinga

Short Volatility Alert: Legend Biotech Corporation ↗

June 17, 2022

On Thursday, shares of Legend Biotech Corporation (NASDAQ: LEGN) experienced volatile short activity. After the activity, the stock price went down -1.38% to $42.96. The...

Via Benzinga

Walmart, Shopify And Some Other Big Stocks Recording Losses On Tuesday ↗

July 27, 2022

U.S. stocks closed lower on Monday, with the Nasdaq Composite dropping more than 200 points. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Legend Biotech Corporation Announces Pricing of Public Offering

July 26, 2022

From Legend Biotech Corporation

Via Business Wire

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗

July 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

Legend Biotech Corporation Announces Proposed Public Offering

July 25, 2022

From Legend Biotech Corporation

Via Business Wire

How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer ↗

June 06, 2022

This biotech stock launched in February to work on CAR-T treatments.

Via Investor's Business Daily

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

June 04, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

June 03, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

June 01, 2022

From Legend Biotech

Via Business Wire

Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022

From Legend Biotech

Via Business Wire

Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal ↗

May 28, 2022

Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...

Via Talk Markets

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗

May 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

May 26, 2022

From Legend Biotech

Via Business Wire

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

May 18, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

May 09, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Announces Participation in Upcoming Investor Conferences

May 06, 2022

From Legend Biotech

Via Business Wire

HFCAA News: 128 Chinese Stocks the SEC Could Delist ↗

May 05, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

Via InvestorPlace

Legend Biotech Announces Appointment of Global Head of Research and Early Development

April 01, 2022

From Legend Biotech Corporation

Via Business Wire

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗

April 01, 2022

Via Benzinga

EMA's CHMP Clears Janssen, Legend's Multiple Myeloma CAR-T Therapy ↗

March 25, 2022

The European Medicines Agency's CHMP

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Receives Positive CHMP Opinion for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

March 25, 2022

From Legend Biotech

Via Business Wire

Flanders Investment and Trade Names Legend Biotech Newcomer of the Year

March 23, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

March 18, 2022

From Legend Biotech

Via Business Wire

Analyst Ratings For Legend Biotech ↗

March 15, 2022

Analysts have provided the following ratings for Legend Biotech (NASDAQ:LEGN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.